We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
47 hedge funds and large institutions have $42.7M invested in Crescent Biopharma in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
0% more funds holding
Funds holding: 47 → 47 (0)
0% less ownership
Funds ownership: 0.58% → 0.57% (-0%)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
21% less call options, than puts
Call options by funds: $450K | Put options by funds: $568K
34% less capital invested
Capital invested by funds: $64.9M → $42.7M (-$22.2M)
Holders
47
Holders Change
–
Holders Change %
0%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
15
Reduced
13
Closed
6
Calls
$450K
Puts
$568K
Net Calls
-$118K
Net Calls Change
-$438K
Top Buyers
| 1 |
Millennium Management
New York
|
+$442K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$335K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$265K |
| 4 |
Two Sigma Investments
New York
|
+$203K |
| 5 |
EP
Eversept Partners
New York
|
+$181K |
Top Sellers
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$799K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$617K |
| 3 |
VF
Virtu Financial
New York
|
-$119K |
| 4 |
HF
HRT Financial
New York
|
-$112K |
| 5 |
D.E. Shaw & Co
New York
|
-$88.7K |
